Search

Displaying results 4001 - 4010 of 5419 in total
  1. Drug

    Carbuterol

    go.drugbank.com/drugs/DB13625
    Experimental

    Categories: Adrenergics for Systemic Use
  2. Drug

    Lapyrium

    go.drugbank.com/drugs/DB09376
    Approved

    Lapyrium is a quaternary ammonium cation used as a surfactant, antistatic agent, and biocide in various cosmetic products . It is commonly found formulated as lapyrium chloride.

  3. Drug

    AER001

    go.drugbank.com/drugs/DB05078
    Investigational

    AER001, an IL4/13 receptor antagonist for severe asthma and eczema currently in Phase 2 studies.

  4. Drug

    R1204

    go.drugbank.com/drugs/DB05118
    Experimental

    R1204 is G-protein-coupled receptor modulator. It is developed for the treatment of depression.

  5. Drug

    SPP1148

    go.drugbank.com/drugs/DB05203
    Experimental

    SPP1148, the most promising compound from a new series of renin inhibitors for the treatment of hypertension and related end-organ disease.

  6. Drug

    TAK-475

    go.drugbank.com/drugs/DB05317
    Investigational

    TAK-475 is a "squalene synthase inhibitor", a type of cholesterol-lowering drug that has not yet been brought to market.

  7. Drug

    Enokizumab

    go.drugbank.com/drugs/DB05555
    Investigational

    A humanized immunoglobulin G1k anti-interleukin-9 mAb.

  8. Drug

    Prolease-r-hFSH

    go.drugbank.com/drugs/DB05826
    Experimental

    Prolease-r-hFSH is a recombinant human follicle stimulating hormone (r-hFSH) with Alkermes' ProLease injectable sustained release drug delivery technology. It provides patients with long term therapeutic benefit from a single administrat...

  9. Drug

    AI-128

    go.drugbank.com/drugs/DB05841
    Experimental

    AI-128 is the first human demonstration of sustained release drug administration in the lung. AI-128 consists of slowly dissolving microspheres designed to control where drug particles go in the lung and how quickly they release their drug.

  10. Drug

    ETC-1001

    go.drugbank.com/drugs/DB05866
    Experimental

    ETC-1001 is Pfizer’s lead oral small molecule product candidate which is intended to be a chronic treatment for individuals with lipid disorders.